PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MD - US58502B1061 - Common Stock
21.29 USD
-0.1 (-0.47%)
21.29 USD
0 (0%)
MD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD may be a bit undervalued, certainly considering the very reasonable score on growth This makes MD very considerable for value investing!
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
MD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MD's Return On Assets of 7.37% is amongst the best of the industry. MD outperforms 89.11% of its industry peers.
MD has a better Return On Equity (18.21%) than 84.16% of its industry peers.
MD has a Return On Invested Capital of 10.25%. This is amongst the best in the industry. MD outperforms 80.20% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.58%.
The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
The Profit Margin of MD (8.44%) is better than 89.11% of its industry peers.
Looking at the Operating Margin, with a value of 12.20%, MD belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
MD has an Altman-Z score of 2.17. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
MD's Altman-Z score of 2.17 is in line compared to the rest of the industry. MD outperforms 49.51% of its industry peers.
MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
MD's Debt to FCF ratio of 2.20 is fine compared to the rest of the industry. MD outperforms 78.22% of its industry peers.
MD has a Debt/Equity ratio of 0.65. This is a neutral value indicating MD is somewhat dependend on debt financing.
MD has a Debt to Equity ratio (0.65) which is in line with its industry peers.
Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.17 |
ROIC/WACC1.14
WACC9.02%
2.3 Liquidity
MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.83, MD is in the better half of the industry, outperforming 71.29% of the companies in the same industry.
A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Quick ratio (1.83) than 74.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 7.64% on average per year.
Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 2.71% on average per year.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.44, the valuation of MD can be described as reasonable.
88.12% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.51.
The Price/Forward Earnings ratio is 9.45, which indicates a very decent valuation of MD.
Based on the Price/Forward Earnings ratio, MD is valued cheaper than 91.09% of the companies in the same industry.
MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.44 | ||
| Fwd PE | 9.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 80.20% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 91.09% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.69 | ||
| EV/EBITDA | 7.2 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MD may justify a higher PE ratio.
A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
21.29
-0.1 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.39%
Inst Owner Change-2.05%
Ins Owners1.9%
Ins Owner Change-0.16%
Market Cap1.83B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (8.6%)
Short Float %4%
Short Ratio3.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)36.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.45%
EPS NY rev (1m)16.25%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)1.13%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.44 | ||
| Fwd PE | 9.45 | ||
| P/S | 0.95 | ||
| P/FCF | 6.69 | ||
| P/OCF | 6.3 | ||
| P/B | 2.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.2 |
EPS(TTM)2.04
EY9.58%
EPS(NY)2.25
Fwd EY10.58%
FCF(TTM)3.18
FCFY14.95%
OCF(TTM)3.38
OCFY15.86%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.24
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.17 |
F-Score8
WACC9.02%
ROIC/WACC1.14
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.44 and the Price/Book (PB) ratio is 2.05.